Comparative Pharmacology
Head-to-head clinical analysis: AGAMREE versus CORTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGAMREE versus CORTRIL.
AGAMREE vs CORTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid receptor agonist; modulates transcription via glucocorticoid response elements, suppressing inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and immune cell activity.
Cortril (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators and suppression of immune response.
Initial dose: 600 mg (6 tablets of 100 mg or 3 tablets of 200 mg) orally once daily for 4 weeks, then 400 mg orally once daily for weeks 5-8; total treatment duration 8 weeks.
Hydrocortisone (Cortril) for adrenal insufficiency: 20-30 mg orally daily divided into two or three doses. For acute conditions, IV or IM hydrocortisone sodium succinate 100 mg every 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3 hours in adults. The half-life may be prolonged in patients with hepatic impairment.
Terminal elimination half-life: 1.5–2.5 hours. Clinically, the biologic half-life (duration of ACTH suppression) is longer (8–12 hours).
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites. Renal excretion of metabolites accounts for about 60%.
Renal (95% as free cortisol and metabolites, primarily tetrahydrocortisol and glucuronide conjugates). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid